# A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase Ⅲ Study to Evaluate the Efficacy and Safety of WD-890 Tablets for the Treatment of Moderate to Severe Plaque Psoriasis

> **NCT07672561** · PHASE3 · RECRUITING · sponsor: **Zhejiang Wenda Pharma Technology LTD.** · enrollment: 375 (estimated)

## Conditions studied

- Moderate to Severe Plaque Psoriasis

## Interventions

- **DRUG:** Drug:WD-890
- **DRUG:** Drug: placebo

## Key facts

- **NCT ID:** NCT07672561
- **Lead sponsor:** Zhejiang Wenda Pharma Technology LTD.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-18
- **Primary completion:** 2026-11-30
- **Final completion:** 2027-07-30
- **Target enrollment:** 375 (ESTIMATED)
- **Last updated:** 2026-06-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07672561

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07672561, "A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase Ⅲ Study to Evaluate the Efficacy and Safety of WD-890 Tablets for the Treatment of Moderate to Severe Plaque Psoriasis". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07672561. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*